Inspecs GroupLSE:SPEC 52 Forward PE Ratio is 14.48 as of Jul. 11, 2026. GuruFocus rates LSE:SPEC with a GF Score™ of 52/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Inspecs Group ranks better than 68.62% on this metric.
Inspecs Group's Forward PE Ratio for today is 14.48.
Inspecs Group (LSE:SPEC) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Inspecs Group Forward PE Ratio Related Terms
Inspecs Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Inspecs Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group Forward PE Ratio Chart
Inspecs Group Annual Data
Trend
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
26.39
24.69
4.98
12.33
7.67
10.75
Inspecs Group Semi-Annual Data
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-06
2024-12
2025-06
2025-12
Forward PE Ratio
74.63
26.39
30.77
24.69
18.15
4.98
13.50
12.33
9.98
7.67
8.17
10.75
LSE:SPEC vs ISRG, BDX, MDLN: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Inspecs Group's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Inspecs Group (LSE:SPEC) has a Forward PE Ratio of 14.48 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Inspecs Group and its competitors. According to the industry distribution chart, Inspecs Group ranks #123 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 31.4%.
Is Inspecs Group's Forward PE Ratio too high?
Inspecs Group's current Forward PE Ratio is 14.48. The Medical Devices & Instruments industry median Forward PE Ratio is 19.17. Inspecs Group's value of 14.48 is 24.5% below this industry median. Based on the distribution chart, Inspecs Group ranks #123 out of 392 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Inspecs Group has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #123 out of 392 companies for Forward PE Ratio. This puts Inspecs Group in the upper half of its industry. The industry median Forward PE Ratio is 19.17. Inspecs Group's value of 14.48 is 24.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.17, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current Forward PE Ratio of 14.48 is 24.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Inspecs Group and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current Forward PE Ratio is 14.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.97 — trading 67.2% above its estimated fair value. The current Forward PE Ratio is 14.48 and 24.5% below the Medical Devices & Instruments industry median of 19.17. Inspecs Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current Forward PE Ratio is 14.48 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.97 is trading 67.2% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
Forward PE Ratio: 14.48
GF Value™: £0.58 vs. price of £0.97 (67.2% above fair value)
Industry Position: 24.5% below the Medical Devices & Instruments median (#123 of 392)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
52GF Score
Get the complete analysis for LSE:SPEC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 